FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | Contact Us | FAQ | Background Info |

Start Over | Back to Search Results

Epinephrine Injection, Auto-Injector
Status: Currently in Shortage
»Date first posted: 05/09/2018
»Therapeutic Categories: Pulmonary/Allergy

Expand all

Impax Laboratories (Revised 10/25/2018)

Company Contact Information:
877-99-Impax(46729); option 2

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
0.15 mg/0.15 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1695-49)	Available	Dear Healthcare Provider Letter Patient Inspection Instructions Dear Healthcare Provider Letter for Expiry Extension for Select Lots of Epinephrine 0.15 mg and 0.30 mg Auto-Injectors	Manufacturing delays
0.3 mg/0.3 mL epinephrine injection, USP, pre-filled auto-injector (two pack)(NDC 0115-1694-49)	Available	Dear Healthcare Provider Letter Patient Inspection Instructions Dear Healthcare Provider Letter for Expiry Extension for Select Lots of Epinephrine 0.15 mg and 0.30 mg Auto-Injectors	Manufacturing delays

Kaleo (Reverified 11/28/2018)

Company Contact Information:
877-30-AUVIQ (1-877-302-8847)

Presentation	Availability and Estimated Shortage Duration	Related Information
Carton containing two AUVI-Q (epinephrine injection, USP) 0.3 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-023-01)	Available	AUVI-Q is readily available and not currently in shortage.
Carton containing two AUVI-Q (epinephrine injection, USP) 0.15 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-022-01)	Available	AUVI-Q is readily available and not currently in shortage.
Carton containing two AUVI-Q (epinephrine injection, USP) 0.1 mg auto-injectors and a single AUVI-Q Trainer (NDC 60842-021-01)	Available	AUVI-Q is readily available and not currently in shortage.

Mylan Specialty (Reverified 02/20/2019)

Company Contact Information:
800-RXMYLAN (1-800-796- 9526)

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
0.3 mg (EpiPen® NDC 49502-500-02) (Authorized Generic NDC 49502-102-02)	Available	Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen® and the authorized generic version, continues to experience manufacturing constraints. Currently, supplies will vary from pharmacy to pharmacy. Mylan, the distributor, is expediting shipments to wholesalers upon receipt from Pfizer. Patients who are experiencing difficulty accessing product should continue to contact Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies. Dear Healthcare Provider Letter for Expiry Extension for Select Lots of EpiPen 0.3 mg Auto-Injectors and its Authorized Generic Dear Healthcare Provider Letter for Potential Label Defect of EpiPen Auto-Injectors and its Authorized Generic	Manufacturing delays
0.15 mg (EpiPen® NDC 49502-501-02) (Authorized Generic NDC 49502-101-02)	Available	Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen® and the authorized generic version, continues to experience manufacturing constraints. Currently, supplies will vary from pharmacy to pharmacy. Mylan, the distributor, is expediting shipments to wholesalers upon receipt from Pfizer. Patients who are experiencing difficulty accessing product should continue to contact Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies. Dear Healthcare Provider Letter for Potential Label Defect of EpiPen Auto-Injectors and its Authorized Generic	Manufacturing delays

Teva Pharmaceuticals (Reverified 02/13/2019)

Company Contact Information:
800-545-8800

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
0.3 mg/mL epinephrine injection, USP, auto-injector (NDC 0093-5986-27)	Available